In the current study, we demonstrate that the loss of infiltrating Tregs not only enhanced early-stage CD8+ TIL effector activity but also inhibited TOX induction, preventing the CD4+ T cell transition into functional exhaustion during tumor progression. The gene discussed is CD8A; the disease is neoplasm.